Dr. S Yousuf Zafar Talks About BMI and Survival Rates in Colorectal Cancer Patients
Dr. S. Yousuf Zafar talks about the association between the body mass index of patients who are starting treatment for colorectal cancer and both the progression free survival and overall survival.
S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, talks about the association between the body mass index (BMI) of patients who are starting treatment for colorectal cancer and both the progression free survival (PFS) and overall survival (OS).
Zafar says that while there was no link to be drawn between PFS and BMI in those patients, there was a connection between higher BMI and a better OS rate.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
